Hangzhou Taibo Pharmaceutical

Hangzhou Taibo Pharmaceutical is a clinical-stage biotechnology company focused on developing innovative small molecule drugs for ophthalmic diseases. The company's primary focus is on addressing unmet medical needs in retinal diseases through multi-target inhibition, specifically targeting the VEGF and TGF-β pathways. Its lead program, TB001, is being evaluated in clinical trials for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Taibo Pharmaceutical aims to revolutionize eye care by developing non-invasive or more effective delivery methods, such as topical eye drops, for conditions that currently require frequent intravitreal injections. The company is led by an experienced scientific team with deep expertise in drug delivery and ophthalmology.